Valuation: Precipio Inc

Market Cap 33.15M 30.2M 27.96M 25.29M 47.44M 3.1B 49.66M 338M 134M 1.67B 124M 122M 5.3B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 34.15M 31.12M 28.8M 26.06M 48.88M 3.19B 51.16M 348M 138M 1.72B 128M 125M 5.46B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.3%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 2017-05-31
Chief Executive Officer 54 2017-06-27
Director TitleAgeSince
Director/Board Member 54 2017-06-27
Director/Board Member 78 2017-09-25
Director/Board Member 67 2017-11-07
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 33.15M
-0.58%-1.53%+20.04%+47.67% 255B
-0.45%-1.98%+2.32%+9.52% 160B
-3.26%-7.42%-27.88%+33.40% 141B
-1.49%-2.74%-55.68%-20.89% 62.31B
-1.28%-1.81%+20.76%+55.28% 59.73B
-0.76%-0.86%+5.52%-12.86% 53.49B
-1.12%+1.35%+21.43%+54.96% 49.43B
-2.06%-1.24%+21.32%+74.31% 44.87B
-5.15%-13.06%-3.69%+48.93% 42.57B
Average +0.85%-3.30%+0.46%+32.26% 97B
Weighted average by Cap. -0.80%-3.60%+1.69%+32.05%

Financials

2024 2025
Net sales 18.53M 16.88M 15.63M 14.14M 26.52M 1.73B 27.76M 189M 74.94M 935M 69.53M 68.07M 2.96B 24.05M 21.91M 20.28M 18.35M 34.42M 2.25B 36.02M 245M 97.25M 1.21B 90.22M 88.33M 3.84B
Net income -4.29M -3.91M -3.62M -3.27M -6.14M -401M -6.43M -43.74M -17.35M -217M -16.09M -15.76M -686M -363K -331K -306K -277K -520K -33.9M -544K -3.7M -1.47M -18.32M -1.36M -1.33M -58.03M
Net Debt -136K -124K -115K -104K -195K -12.7M -204K -1.39M -550K -6.86M -510K -500K -21.74M 1M 913K 845K 764K 1.43M 93.58M 1.5M 10.22M 4.05M 50.57M 3.76M 3.68M 160M
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-